|[December 05, 2013]
NPS Pharmaceuticals to Webcast Investor and Analyst Event
BEDMINSTER, N.J. --(Business Wire)--
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that it will
host an Investor and Analyst Event for its research analysts and
institutional investors on Friday, December 6 at 8:30 a.m. ET in New
York City. Francois Nader, M.D., president and chief executive officer
of NPS, will host the event along with other key members of NPS senior
management. Expert medical leaders will also be featured speakers at the
The meeting will primarily focus on the global commercial opportunity
for Natpara® in hypoparathyroidism. The company will also provide an
update on its lead commercial product Gattex®/Revestive® in adult Short
A live webcast and replay of the meeting can be accessed by visiting
calendar of events page in the Investor section of the NPS website at http://www.npsp.com/calendar.
All presentation materials will be made available as part of the
webcast. The replay will be available approximately three hours after
the event has concluded.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and
delivering therapies that transform the lives of patients with rare
diseases worldwide. The company's lead product, Gattex®
(U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is
approved for adult Short Bowel Syndrome (SBS) patients who are dependent
on parenteral support. NPS has also developed Natpara® (rhPTH [1-84])
for the treatment of hypoparathyroidism and submitted its marketing
application to the U.S. Food and Drug Administration in October 2013.
NPS's earlier stage pipeline includes NPSP795, a calcilytic compound
with potential application in rare disorders involving increased calcium
receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS
complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen,
GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.
[ Back To Technology News's Homepage ]